Artiva Biotherapeutics, Inc. (ARTV) AI Stock Analysis

• Market Cap: $87.69M
• Dividend Yield: N/A
• Average Volume (3M): 4.17M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.21
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 96
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.87
• Shares Outstanding: 24,425,762
• 10 Day Avg. Volume: 12,277,267
• 30 Day Avg. Volume: 4,166,063
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -1.05
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 1.16
• 1Y Price Target: $15.75
• Price Target Upside: 317.77% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $5.00 ▲(32.63% Upside)

Artiva Biotherapeutics, Inc. has potential due to its revenue growth and positive technical indicators. However, significant financial challenges, including negative profitability and cash flow issues, weigh heavily on the overall score. The stock's valuation is also a concern due to ongoing losses.

Positive Factors

Revenue Growth

The company's revenue growth trajectory indicates increasing market acceptance and potential for future sales expansion, crucial for long-term success.

Equity Improvement

Improvement in equity suggests enhanced financial stability, which can support future growth initiatives and improve investor confidence.

Innovative Product Pipeline

A strong focus on innovative NK cell therapies positions Artiva as a leader in cutting-edge cancer treatments, offering long-term competitive advantages.

Negative Factors

Profitability Challenges

Ongoing profitability challenges could hinder reinvestment and growth, necessitating continued reliance on external funding sources.

Cash Flow Difficulties

Negative free cash flow highlights operational inefficiencies and may limit the company's ability to fund new projects without external financing.

High Debt-to-Equity Ratio

A high debt-to-equity ratio can strain financial resources, increasing risk and potentially limiting future strategic options.

Artiva Biotherapeutics, Inc. Business Overview & Revenue Model

Company Description

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

How the Company Makes Money

Artiva Biotherapeutics generates revenue primarily through the development and commercialization of its cell therapy products. The company may secure funding through various channels, including equity financing, grants, and collaborations with larger pharmaceutical companies. Key revenue streams could include upfront payments, milestone payments, and royalties from partnerships and licensing agreements related to its NK cell therapy products. Additionally, Artiva could generate income through clinical trial collaborations and research agreements aimed at advancing its therapeutic candidates, as well as potential future sales of approved therapies once they enter the market.

Artiva Biotherapeutics, Inc. Financial Statement Overview

Summary

Artiva Biotherapeutics, Inc. shows revenue growth and improved equity, but faces significant profitability and cash flow challenges. The negative net profit margin and reliance on external financing are major concerns.

Income Statement

Artiva Biotherapeutics, Inc. has demonstrated significant revenue growth from $2,002,000 in 2021 to $251,000 in 2024, indicating a positive trajectory. However, the company is still facing substantial net losses, with a net profit margin of -232.9% in 2024. The EBIT and EBITDA margins are also negative, reflecting ongoing operational challenges.

Balance Sheet

The balance sheet shows improvement in stockholders' equity, moving from negative to positive in 2024, but the company still has a high debt-to-equity ratio due to previous negative equity. The equity ratio improved to 89.1% in 2024, showing enhanced financial stability despite previous challenges.

Cash Flow

Cash flow analysis indicates difficulties in generating positive free cash flow, with a free cash flow of -$55.7 million in 2024. The operating cash flow to net income ratio is negative, pointing to challenges in converting earnings to cash. There is a growth in financing cash flow, reflecting reliance on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	251.00K	33.49M	4.93M	2.00M	0.00
Gross Profit	0.00	251.00K	33.49M	4.93M	2.00M	0.00
EBITDA	-79.71M	-64.85M	-28.41M	-58.67M	-71.58M	-17.72M
Net Income	-68.25M	-58.49M	-27.70M	-58.39M	-71.83M	-17.99M
Balance Sheet
Total Assets	169.39M	209.58M	105.11M	133.05M	169.93M	29.23M
Cash, Cash Equivalents and Short-Term Investments	142.37M	185.43M	76.97M	102.53M	160.92M	25.44M
Total Debt	13.22M	14.35M	16.91M	19.45M	1.74M	2.12M
Total Liabilities	20.35M	22.94M	267.13M	273.75M	258.78M	50.80M
Stockholders Equity	149.04M	186.64M	-162.01M	-140.70M	-88.86M	-21.57M
Cash Flow
Free Cash Flow	-70.81M	-55.67M	-50.69M	-57.13M	-17.03M	-13.82M
Operating Cash Flow	-69.08M	-55.03M	-47.43M	-50.83M	-15.30M	-13.54M
Investing Cash Flow	-100.50M	-120.46M	-25.98M	-6.30M	-1.72M	-284.00K
Financing Cash Flow	164.01M	162.23M	24.39M	-1.26M	152.75M	37.40M

Artiva Biotherapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.77
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ARTV, the sentiment is Neutral. The current price of 3.77 is below the 20-day moving average (MA) of 3.96, above the 50-day MA of 3.30, and above the 200-day MA of 3.13, indicating a neutral trend. The MACD of 0.34 indicates Positive momentum. The RSI at 49.10 is Neutral, neither overbought nor oversold. The STOCH value of 4.93 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ARTV.

Artiva Biotherapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	56 Neutral	$76.47M	-0.69	-69.96%	―	-99.64%	-59.17%
ARTV	52 Neutral	$87.69M	-1.16	-86.18%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ABVC	43 Neutral	$68.53M	-12.64	-39.93%	―	186.84%	89.16%
PLRX	37 Underperform	$98.83M	-0.47	-67.55%	―	―	-9.87%
JSPR	35 Underperform	$50.54M	-0.30	-146.87%	―	―	-17.96%
ACET	27 Underperform	$105.79M	-0.53	-64.39%	―	―	48.45%

Artiva Biotherapeutics, Inc. Corporate Events

Artiva Biotherapeutics Advances with Promising NK Cell Therapy Study

Artiva Biotherapeutics, Inc. is conducting a Phase 2a clinical study titled ‘An Open-label Phase 2a Study to Evaluate the Safety and Efficacy of AlloNK®, an Allogeneic Cord Blood-derived NK Cell Therapy, in Combination With Rituximab in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.’ The study aims to assess the safety and efficacy of AlloNK®, a non-genetically modified NK cell therapy, combined with Rituximab for treating refractory rheumatoid arthritis, Sjögren’s disease, idiopathic inflammatory myopathies, and systemic sclerosis. This research is significant as it explores innovative treatments for challenging rheumatologic conditions.

Artiva Biotherapeutics Advances Lupus Treatment with Innovative NK-Cell Therapy

Artiva Biotherapeutics, Inc. is conducting a Phase 1 clinical trial titled A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood-Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus. The study aims to assess the safety, tolerability, and preliminary activity of AB-101, a natural killer cell therapy, in combination with B-cell depleting monoclonal antibodies in patients with relapsed or refractory lupus nephritis or systemic lupus erythematosus.

Artiva Biotherapeutics Advances in Cancer Therapy with GCC2005 Study Update

Study Overview: The clinical study titled A Phase 1, Multicenter Trial to Assess the Safety, Tolerability, and Preliminary Efficacy of GCC2005 With Lymphodepleting Chemotherapy in Treatment of Patients With Relapsed or Refractory NK and T-cell Malignancies aims to evaluate the safety, tolerability, and preliminary efficacy of GCC2005 in patients with relapsed or refractory NK and T-cell malignancies. This study is significant as it targets patients who have undergone at least two prior lines of therapy, offering a potential new treatment avenue.

Artiva Biotherapeutics Reports Progress in Clinical Trials

Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing accessible cell therapies for autoimmune diseases and cancers, utilizing its lead program AlloNK® to enhance treatment efficacy.